Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-6bf8c574d5-7jkgd Total loading time: 0 Render date: 2025-02-23T13:01:03.504Z Has data issue: false hasContentIssue false

Pimavanserin

Published online by Cambridge University Press:  20 February 2025

K. Ray Chaudhuri ,
Peter Jenner ,
Valentina Leta ,
Shelley Jones  and
Iro Boura
K. Ray Chaudhuri
Affiliation:
King's College London
Peter Jenner
Affiliation:
King's College London
Valentina Leta
Affiliation:
King's College London
Shelley Jones
Affiliation:
King's College London
Iro Boura
Affiliation:
St. George General Hospital of Chania, Crete, Greece
Get access

Summary

Pimavanserin (1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-[[4-(2-methylpropoxy)pneyl]methyl]urea) has a molecular weight of 427.6 and an empirical formula of C25H34FN3O2 (free base).

Type
Chapter
Information
The Movement Disorders Prescriber's Guide to Parkinson's Disease , pp. 345 - 353
Publisher: Cambridge University Press
Print publication year: 2025

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Suggested Reading

Black, K.J., et al., Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson’s disease psychosis: an expert consensus. CNS Spectr, 2018. 23(6): p. 402–413.CrossRefGoogle ScholarPubMed
Bozymski, K.M., Lowe, D.K., Pasternak, K.M., Gatesman, T.L., and Crouse, E.L.. Pimavanserin: A Novel Antipsychotic for Parkinson’s Disease Psychosis. Ann Pharmacother, 2017. 51(6): p. 479–487.CrossRefGoogle ScholarPubMed
Cummings, J., Isaacson, S., Mills, R., Williams, H., Chi-Burris, K., Corbett, A., Dhall, R., and Ballard, C., Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet, 2014. 383(9916): p. 533–40.CrossRefGoogle ScholarPubMed
Mosholder, A.D., et al., Mortality Among Parkinson’s Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries. Am J Psychiatry, 2022. 179(8): p. 553–561.CrossRefGoogle Scholar
Sahli, Z.T. and Tarazi, F.I., Pimavanserin: novel pharmacotherapy for Parkinson’s disease psychosis. Expert Opin Drug Discov, 2018. 13(1): p. 103–110.CrossRefGoogle ScholarPubMed

References

Ballard, C, Banister, C, Khan, Z, Cummings, J, Demos, G, Coate, B, Youakim, JM, Owen, R, Stankovic, S. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer’s disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study. Lancet Neurol 2018; 17(3): 213–222.CrossRefGoogle ScholarPubMed
Bozymski, KM, Lowe, DK, Pasternak, KM, Gatesman, TL, Crouse, EL. Pimavanserin: a novel antipsychotic for Parkinson’s disease psychosis. Ann Pharmacother 2017; 51(6): 479–487.CrossRefGoogle ScholarPubMed
Cummings, J, Ballard, C, Tariot, P, Owen, R, Foff, E, Youakim, J, Norton, J, Stankovic, S. Pimavanserin: potential treatment for dementia-related psychosis. J Prev Alzheimers Dis 2018; 5(4): 253–258.CrossRefGoogle ScholarPubMed
DeKarske, D, Alva, G, Aldred, JL, Coate, B, Cantillon, M, Jacobi, L, Nunez, R, Norton, JC, Abler, V. An open-label, 8-week study of safety and efficacy of pimavanserin treatment in adults with Parkinson’s disease and depression. J Parkinsons Dis 2020; 10(4): 1751–1761.CrossRefGoogle Scholar
Espay, AJ, Guskey, MT, Norton, JC, Coate, B, Vizcarra, JA, Ballard, C, Factor, SA, Friedman, JH, Lang, AE, Larsen, NJ, Andersson, C, Fredericks, D, Weintraub, D. Pimavanserin for Parkinson’s disease psychosis: effects stratified by baseline cognition and use of cognitive-enhancing medications. Mov Disord 2018; 33(11): 1769–1776.CrossRefGoogle ScholarPubMed
Hawkins, T, Berman, BD. Pimavanserin: a novel therapeutic option for Parkinson disease psychosis. Neurol Clin Pract 2017; 7(2): 157–162.CrossRefGoogle ScholarPubMed
Horn, S, Richardson, H, Xie, SX, Weintraub, D, Dahodwala, N. Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson’s disease and dementia with Lewy bodies. Parkinsonism Relat Disord 2019; 69: 119–124.CrossRefGoogle ScholarPubMed
Isaacson, SH, Coate, B, Norton, J, Stankovic, S. Blinded SAPS-pd assessment after 10 weeks of pimavanserin treatment for Parkinson’s disease psychosis. J Parkinsons Dis 2020; 10(4): 1389–1396.CrossRefGoogle ScholarPubMed
Meltzer, HY, Mills, R, Revell, S, Williams, H, Johnson, A, Bahr, D, Friedman, JH. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of Parkinson’s disease psychosis. Neuropsychopharmacology 2010; 35(4): 881–892.CrossRefGoogle ScholarPubMed
Nasrallah, HA, Fedora, R, Morton, R. Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist. Schizophr Res 2019; 208: 217–220.CrossRefGoogle ScholarPubMed
Pimavanserin. In: Brayfield, A (Ed.), Martindale: The Complete Drug Reference. London: The Royal Pharmaceutical Society of Great Britain. Accessed on 4 December 2022 via www.medicinescomplete.com.Google Scholar
Schneider, LS. The safety of pimavanserin for Parkinson’s disease and efforts to reduce antipsychotics for people with dementia. Am J Psychiatry 2022; 179(8): 519–521.CrossRefGoogle ScholarPubMed
Tariot, PN, Cummings, JL, Soto-Martin, ME, Ballard, C, Erten-Lyons, D, Sultzer, DL, Devanand, DP, Weintraub, D, McEvoy, B, Youakim, JM, Stankovic, S, Foff, EP. Trial of pimavanserin in dementia-related psychosis. N Engl J Med 2021; 385(4): 309–319.CrossRefGoogle ScholarPubMed
Webster, P. Pimavanserin evaluated by the FDA. Lancet 2018; 391(10132): 1762.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Pimavanserin
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.037
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Pimavanserin
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.037
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Pimavanserin
  • K. Ray Chaudhuri, King's College London, Peter Jenner, King's College London, Valentina Leta, King's College London, Shelley Jones, King's College London, Iro Boura, St. George General Hospital of Chania, Crete, Greece
  • Book: The Movement Disorders Prescriber's Guide to Parkinson's Disease
  • Online publication: 20 February 2025
  • Chapter DOI: https://doi.org/10.1017/9781009222648.037
Available formats
×